Hepatocellular Carcinoma Pipeline Analysis: Over 80 Companies Working to Improve Treatment Space | DelveInsight

0

DelveInsight’s “Hepatocellular Carcinoma Pipeline Insight, 2022” report provides comprehensive insights on over 80 companies and over 80 drugs in development in the hepatocellular carcinoma pipeline landscape. It covers pipeline drug profiles, including clinical and non-clinical stage products. It also covers therapeutic evaluation by product type, stage, route of administration and molecule type. It further highlights inactive pipeline products in this space.

Key Takeaways from the Hepatocellular Carcinoma Pipeline Insight Report

  • by DelveInsight Hepatocellular carcinoma The pipeline report describes a robust space with more than 80 active players working to develop more than 80 pipeline therapies for hepatocellular carcinoma.
  • Major hepatocellular carcinoma companies such as Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Innovent Biologics, Eli Lilly and Company, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Jiangsu Hengrui Medicine, Shenogen Pharma and others would bring significant change in hepatocellular carcinoma.
  • Promising treatments in the hepatocellular carcinoma pipeline such as lenvatinib, pembrolizumab (200mg), tivozanib, durvalumab, sorafenib, enzalutamide, AZD9150, GC33(RO5137382), mapatumumab and others.
  • Companies and academics are working to assess challenges and seek out opportunities that can influence hepatocellular carcinoma R&D. The therapies under development are focused on new approaches to treat/improve hepatocellular carcinoma.
  • In the report, a detailed description of the drug is given including the mechanism of action of the drug, clinical studies, NDA approvals (if any) and product development activities including technology, carcinoma collaborations hepatocellular, licensing, mergers and acquisitions, financing, designations and other product-related details.

Get an overview of the hepatocellular carcinoma pipeline landscape @ Hepatocellular Carcinoma Emerging Therapies

Overview of Hepatocellular Carcinoma

Hepatocellular carcinoma (HCC) is a rare disease in the United States, but the most common primary liver tumor. Most people have underlying liver disease such as hepatitis B or C virus infection, or non-alcoholic fatty liver disease. Most people have cirrhosis, which is liver scarring that can occur as a result of chronic liver disease. If HCC is caught early, curative treatments can be offered. However, HCC often causes no symptoms, especially early in the course of the disease. If HCC is diagnosed at a late stage, patients may not be able to receive curative treatments, and care is then directed towards a better quality of life. Although HCC does not necessarily cause symptoms, many people will have symptoms caused by the underlying liver disease. The exact cause of HCC is not fully understood. Most people have no noticeable symptoms associated with hepatocellular carcinoma. They may have symptoms related to cirrhosis of the liver which may become more difficult to control. Due to underlying liver disease and HCC, the liver may become decompensated. This means that an organ, in this case the liver, is struggling to compensate for the effects of the disease. Symptoms of liver decompensation may include fluid buildup in the abdomen (ascites), abnormal enlargement of the spleen (splenomegaly), high pressure in the main vein that supplies the liver (portal hypertension), yellowing of the skin , eyes and mucous membranes due to the accumulation of bile in the body (jaundice) and hepatic encephalopathy, a condition in which toxins that are normally eliminated by the liver are not removed and instead travel through the bloodstream to the brain.

Latest Breakthroughs in the Hepatocellular Carcinoma Treatment Landscape

  • SCT I10A is a drug used to treat hepatocellular carcinoma. SCT I10A is being actively studied in Study II/III; no studies for this drug have been completed so far.
  • FOTIVDA® (tivozanib) is a once-daily vascular endothelial growth factor receptor (VEGFR)-differentiated tyrosine kinase (TKI) inhibitor. It is a potent, selective inhibitor of VEGFR 1, 2 and 3 with a long half-life designed to improve efficacy and tolerability. AVEO received U.S. Food and Drug Administration (FDA) approval for FOTIVDA in March 2021 for the treatment of adult patients with relapsed or refractory advanced renal cell carcinoma (RCC) after two prior systemic therapies or more. FOTIVDA was approved in August 2017 in the European Union and in other countries in the territory of its partner EUSA Pharma for the treatment of adult patients with advanced RCC. Tivozanib has been shown to significantly reduce the production of regulatory T cells in preclinical models. Tivozanib was discovered by Kyowa Kirin (KKC) and is also being studied as a new formulation by KKC in acute wet macular degeneration.

Request a Sample and Learn about Recent Advances in Hepatocellular Carcinoma Treatment Drugs – Hepatocellular Carcinoma Pipeline Report

Emerging drugs for hepatocellular carcinoma

  • Tivozanib: AVEO Oncology
  • SCT-I10A: Sinocelltech

DelveInsight’s hepatocellular carcinoma pipeline report covers more than 80 products in various stages of clinical development, such as

  • Late-stage products (Phase III)
  • Intermediate products (Phase II)
  • Product at an early stage (Phase I) as well as details of
  • Candidates in the preclinical and discovery phase
  • Abandoned and Inactive Candidates

Learn about Emerging Therapies in the Hepatocellular Carcinoma Pipeline @ Clinical Trials in Hepatocellular Carcinoma

Scope of the Hepatocellular Carcinoma Pipeline Report

  • Coverage – Global
  • Therapeutic assessment of hepatocellular carcinoma
    • Assessment by product type
    • Assessment by stage and type of product
    • Evaluation by route of administration
    • Assessment by stage and route of administration
    • Evaluation by type of molecule
    • Evaluation by stage and type of molecule
  • Hepatocellular carcinoma societies- Sinocelltech, AVEO Oncology, Oxford BioTherapeutics, Beijing SyngenTech, Surface Oncology, Novartis Oncology, Array BioPharma, Taizhou Hanzhong Pharmaceuticals, Akeso Biopharma, Innovent Biologics, Eli Lilly and Company, Shanghai Henlius Biotech, Chugai Pharmaceutical, CStone Pharmaceuticals, Jiangsu Hengrui Medicine, Shenogen Pharmacy and others
  • Hepatocellular carcinoma therapies- lenvatinib, pembrolizumab (200mg), tivozanib, durvalumab, sorafenib, enzalutamide, AZD9150, GC33 (RO5137382), mapatumumab and others

Dive into rich information about new drugs for the treatment of hepatocellular carcinoma, visit @ Drugs for hepatocellular carcinoma

Contents

  1. Introduction
  2. Summary
  3. Hepatocellular carcinoma: overview
  4. Pipeline therapeutics
  5. Therapeutic assessment
  6. Hepatocellular Carcinoma – Analytical Perspective from DelveInsight
  7. Late-stage products (pre-registration)
  8. Late stage products (Phase II/III)
  9. SCT-I10A: Sinocelltech
  10. Mid-term products (Phase II)
  11. Products in the preclinical and discovery phase
  12. Inactive products
  13. Hepatocellular carcinoma key companies
  14. Hepatocellular carcinoma key products
  15. Hepatocellular Carcinoma – Unmet Needs
  16. Hepatocellular Carcinoma – Market Drivers and Barriers
  17. Hepatocellular Carcinoma – Future Perspectives and Conclusion
  18. Opinions of analysts on hepatocellular carcinoma
  19. Hepatocellular carcinoma key companies
  20. Annex

For more information on treatments in the hepatocellular carcinoma pipeline, contact @ Hepatocellular Carcinoma Societies

About Us

DelveInsight is a business consulting and market research firm, providing expert healthcare business solutions and offering premier consulting services in the areas of R&D, strategy formulation, operations, competitive intelligence, competitive landscape design and mergers and acquisitions.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact person: Yash Bhardwaj
E-mail: Send an email
Call: 9193216187
Address:304 S. Jones Boulevard #2432
Town: Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Share.

Comments are closed.